AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.98
-0.02 (-0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.00
Open4.00
Bid3.80 x 3100
Ask4.30 x 1800
Day's Range3.91 - 4.07
52 Week Range3.31 - 15.00
Volume442,892
Avg. Volume808,106
Market Cap179.933M
Beta (3Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)-3.81
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.56
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin

    -- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment.

  • GlobeNewswire20 days ago

    Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial.

  • GlobeNewswirelast month

    Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant gram-negative ...

  • GlobeNewswirelast month

    Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    --Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT--. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing ...

  • GlobeNewswire2 months ago

    Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018-- Achaogen, Inc., a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today highlighted ...

  • Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

    Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AKAO earnings conference call or presentation 6-Aug-18 8:30pm GMT

    Q2 2018 Achaogen Inc Earnings Call

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Northeast, Hurco Companies, PGT, Bassett Furniture Industries, Insys Therapeutics, and Achaogen — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northeast ...

  • GlobeNewswire2 months ago

    Achaogen to Present at the Wedbush PacGrow Healthcare Conference

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference taking place August 14 to 15, 2018 in New York City. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, August 14th, 2018. A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com.

  • The Wall Street Journal3 months ago

    [$$] Drug Company Achaogen Expresses Doubt About Its Viability

    Inc., a publicly traded drug company that has received financial support from the Bill & Melinda Gates Foundation, raised a “going concern” warning in a regulatory filing Monday, alerting investors it is starting to run low on cash. The South San Francisco, Calif.-based company, which last month said it plans to cut more than a quarter of its workforce, said it had unrestricted cash, cash equivalents and short-term investments of $100.5 million and an accumulated deficit of $470 million. Achaogen said it would try to raise additional funds through equity or debt financings, government contracts, collaborations and commercial sales of Zemdri, its only approved product and which became available last month.

  • New Strong Sell Stocks for August 7th
    Zacks3 months ago

    New Strong Sell Stocks for August 7th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates

    Achaogen (AKAO) delivered earnings and revenue surprises of -30.43% and 71.95%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Achaogen: 2Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.20. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...

  • GlobeNewswire3 months ago

    Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    --ZEMDRI, approved in the U.S. for the treatment of adults with complicated urinary tract infections--. --Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first ...

  • ACCESSWIRE3 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...

  • GlobeNewswire3 months ago

    CMS Grants New Technology Add-on Payment to ZEMDRI™ (plazomicin)

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ZEMDRI when administered in the hospital inpatient setting. In the final rule concerning Hospital Inpatient Prospective Payment Systems and Fiscal Year 2019 Rates, CMS stated that “ZEMDRI offers a substantial clinical improvement for patients who have limited or no alternative treatment options because it is a new antibiotic that offers a treatment option for a patient population unresponsive to currently available treatments” and that “ZEMDRI meets all the criteria for approval of new technology add-on payments.” Additional information on the final rule and its discussion of NTAP and ZEMDRI can be found online at: HIPPS.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...

  • GlobeNewswire3 months ago

    Achaogen Announces Strategic Update to Align Operations with Commercial and Clinical Development Priorities

    Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced a strategic update and corporate restructuring to focus resources on the successful commercialization of ZEMDRITM in the United States, the Marketing Authorization Application (MAA) filing for ZEMDRI in the European Union, and continued development of the C-Scape program. Consistent with the Company’s mission, Achaogen’s research and development efforts will focus on C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, and new aminoglycoside antibiotics, both of which have non-dilutive funding commitments.

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • How Much Upside Do Analysts See in ViewRay Stock?
    Market Realist4 months ago

    How Much Upside Do Analysts See in ViewRay Stock?

    ViewRay (VRAY) is focused on manufacturing and commercializing MRIdian, its magnetic resonance (or MR) image-guided radiation therapy system, which uses MRI and external beam radiation therapy to concurrently image and treat cancer patients. In February 2017, it received 510(k) clearance from the Food and Drug Administration (or FDA) to market MRIdian Linac. In July 2018, six of the total seven analysts covering ViewRay have given the stock a “buy” or higher rating, while one analyst has given it a “sell” rating.